© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Discovery of cephalosporins transformed infectious disease treatment after researchers at the University of Oxford isolated these compounds from Acremonium in the late 1940s. Progress in chemical synthesis unlocked new possibilities when the core cephem structure was modified, leading to better stability and a broader spectrum. 7-AMCA, or 7-Amino-3-Methoxymethyl-3-Cephem-4-Carboxylic Acid, stands out as a foundational nucleus in the cephalosporin class, critical for building third-generation agents such as Cefpodoxime Proxetil. Messy wars with penicillin resistance shaped the need for newer options. Medicinal chemists leaned into modifying the nucleus at the 3-position, which ushered in molecules like 7-AMCA that could sidestep resistance, remain orally bioavailable, and maintain activity against hard-to-treat bugs. Pharmaceutical companies recognized the potential; investments in synthetic routes and production rose through the 1980s. New antibiotics gained shelf space and prescription pads. Modern versions, like Cefpodoxime, trace their lineage directly to tweaks in this tiny portion of the molecule.
7-AMCA serves as a key intermediate for the semi-synthetic production of orally administered cephalosporins, especially Cefpodoxime Proxetil. It provides a sturdy backbone for establishing essential pharmacological features, offering advantages in spectrum and resistance profile compared to earlier generations. Most manufacturers use the nucleus in large-scale synthesis, appreciating its blend of structural rigidity and easy modification at strategic points. Genuine 7-AMCA finds steady demand at facilities churning out formulations for pediatric and adult use, where reliable absorption and predictable metabolic breakdown make all the difference between a script filled or passed over. Cefpodoxime Proxetil’s widespread use for respiratory and urinary tract infections owes much to this chemical heart. Regulatory agencies establish verified standards for the compound, reinforcing supply chains and ensuring consistent quality in national drug programs.
Pure 7-AMCA comes as a pale yellow or off-white crystalline powder, nearly odorless, and firmly bitter on the tongue. Its molecular formula, C10H12N4O5S2, gives it a moderate molecular mass of 348.4 g/mol, which sits in an ideal range for absorption after oral ingestion. Melting points read between 190 to 195°C. The compound displays weak solubility in water at room temperature, which chemical engineers account for by using solvents or creating salts during large-scale isolation. The nucleus features a distinctive β-lactam ring fused to a dihydrothiazine ring, granting stability but requiring careful storage in cool and dry places to avoid degradation. The 3-methoxymethyl group at the core increases the molecule’s resistance to β-lactamase cleavage, a property that matters when tackling bacteria intent on staying one step ahead of common antibiotics.
Authentic 7-AMCA for pharmaceutical use meets tight benchmarks for purity, heavy metal content, and known storage stability. Analytical chemists run tests like HPLC and NMR to confirm identity, and regulators require batch documentation up to international standards. Suppliers must mark containers with manufacturing data, lot numbers, shelf life, and safe-handling instructions. Buyers ask for quality certificates, which detail impurity limits below 0.5% and specific optical rotations; these finely tuned details reflect years of research linking molecule integrity to the potency and tolerability of the finished drug. A typical shipping drum displays hazard codes, a QR-code reference, and direct contact numbers for compliance teams. Any slip in specification means batches fail regulatory review, losing manufacturers’ reputation and market share.
Large producers lean on multi-step synthesis protocols, typically using 7-ACA (7-Aminocephalosporanic Acid) as a precursor. First, chemists shield reactive groups on 7-ACA with protecting agents, then introduce a methoxymethyl group at the 3-position using an alkylating agent. Catalytic hydrogenation and hydrolysis reactions play critical roles at certain steps, each monitored through process analytics to maximize yield and limit byproducts. Organic solvents such as DMF or acetonitrile help dissolve intermediates at certain points, while tempers run high in the lab whenever scaling up to industrial reactors. Once the synthetic sequence wraps up, crystalline 7-AMCA precipitates, filtered through vacuum systems and washed to remove traces of reactants and metal catalysts. Each lot is characterized by infrared spectroscopy, then packed under nitrogen. Sometimes researchers develop tweaks—both for higher efficiency and cleaner output, reflecting serious efforts to minimize waste and protect staff from exposure.
7-AMCA allows stepwise modification at its amino and carboxylate groups, which opens the way to thousands of new cephalosporin analogues. Chemists often use acylation at the 7-amino group to tack on unique side chains, affecting both oral bioavailability and antibacterial spectrum. Beta-lactam ring integrity must be preserved through pH control and gentle temperatures; hydrolysis is a constant threat, as water and warmth quickly spoil entire reactor runs. Oxidizing or reducing the sulfur atom, or altering methyl substituents on the dihydrothiazine, can dial activity up or down based on the clinical target. Functionalizing the core gives companies the flexibility to chase new regulatory approvals or fight emerging resistance from tricky pathogens. Each derivative finds its own place in therapy as doctors discover better matches for regional patterns of disease or evolving hospital infection trends.
7-AMCA gets listed under several scientific and trade names. These include: 7-Amino-3-methoxymethyl-3-cephem-4-carboxylic acid, 7-Amino-3-(methoxymethyl)-3-cephem-4-carboxylic acid, and its abbreviation 7-AMCA. Firms marketing intermediates for contract research outfits sometimes use coded designations, but established pharmaceutical indexes reference the main structure. Catalogs from leading chemical suppliers show export grade 7-AMCA distinct from research-only grades based on batch size, risk classification, and level of regulatory oversight.
Occupational health rules covering 7-AMCA draw from decades of studies on β-lactam sensitization. Factory workers wear masks, gloves, and industrial-grade goggles; dust from the powder can provoke allergic reactions, particularly among those with a history of penicillin exposure. Most plants install advanced ventilation and closed transfer systems to keep airborne concentrations low. Spill response protocols call for immediate containment and careful decontamination, as residues can linger on surfaces and sensitize both staff and equipment. Personnel complete annual retraining in handling hazardous intermediates. Transport gets tightly regulated, with packaging inspected for leaks or breakage before dispatch. Local authorities require rapid incident reporting and full documentation whenever exposure or contamination incidents occur, and leading firms welcome audits as a badge of responsible manufacturing.
The broadest footprint of 7-AMCA appears in production lines for oral cephalosporins. Finished products, such as Cefpodoxime Proxetil, reach hospitals, clinics, and pharmacies in dozens of countries. These medicines treat common respiratory and urinary tract infections, and give pediatricians options for children who struggle with recurrent ear or throat infections. Outside direct clinical use, some research teams order 7-AMCA for structure-activity relationship experiments, running tests on novel side chains or saddling the nucleus with fluorescent probes. Veterinary medicine gets a piece of the action as well, as companies look to treat complicated infections in livestock without using older antibiotics that breed resistance. In national stockpile programs, reliable cephalosporins sourced from high-grade intermediates remain a safety net against unpredictable outbreaks.
Ongoing research pivots around two main goals: staying one step ahead of resistant bacteria and improving the oral bioavailability of cephalosporins. Medicinal chemists trust the 7-AMCA nucleus because it tolerates creative modifications at its amino, carboxyl, and methoxymethyl substituents. University labs routinely publish findings on new analogues that demonstrate unexpected power against extended-spectrum β-lactamase (ESBL) producers. Collaborative projects between academic teams and industry explore green synthesis methods, aiming to curb hazardous waste during production. Each minor tweak to the core structure can yield fresh patent filings, drawing competitive pressure and also offering hope for new generics when older formulations lose their market edge. Next-generation cephalosporins with immune-modulating or targeting properties all trace their early work back to a nucleus like 7-AMCA. Better software for predicting protein binding and enzyme resistance can direct chemists where to invest their next development cycles, turning hard data into more tailored drugs.
Toxicological studies on 7-AMCA focus on its allergenic potential, especially in workers handling raw intermediates. Animal models get exposed to precise dosages, monitored for immunological and hepatic reactions. These findings inform worker safety limits and shape guidelines for leftover residue in finished products, which must sit well below internationally accepted thresholds. Companies participating in preclinical development test for mutagenicity and teratogenic risk, seeking confidence that no undiagnosed hazard slips through the pipeline. Monitoring programs track reported adverse effects among factory and laboratory staff, using early-warning signals to update training, PPE, and procedural rules. Regulatory authorities conduct audits that blend paperwork review with unexpected field checks, reinforcing a safety culture that has kept major incidents rare in established production facilities.
Antibiotic resistance keeps every major health authority on full alert, continually driving demand for structurally robust, easily modified compounds like 7-AMCA. As resistance genes travel across borders and older drugs lose power, chemists and clinicians look for new cephalosporins that can leapfrog today’s toughest pathogens. Policy makers invest in global surveillance, hoping to pin down hotspots before resistance spills into broader communities. Environmental regulations push companies to upgrade synthesis methods, swapping out older, polluting steps for new protocols that shrink the chemical footprint. Startups pitch enzyme-catalyzed reactions as cleaner and cheaper alternatives, trimming operational costs and minimizing residual contamination. Generics manufacturers grow increasingly skilled at duplicating the critical steps, promising wider access when market exclusivity expires. Research outfits dive into high-throughput screening, cataloguing thousands of possible 7-AMCA derivatives with only a few coming through preclinical trials into finished medicines for tomorrow’s cases. This evolving pipeline continues to rely on strong stewardship of ingredients, tight regulatory frameworks, and an eye on the complex web that connects bench science to real patients and public health.
Antibiotic development keeps leaning on some essential chemical foundations. One such building block, 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid, or 7-AMCA, isn’t a household name, yet it's found in some everyday prescriptions. Let’s zoom in on how the nucleus of cefpodoxime proxetil drives infection treatment, and what its story means for public health.
Years spent working with pharmacists exposed me to rows of compounds bearing complicated names, tucked away behind the simple labels customers see at the counter. 7-AMCA is one of those behind-the-scenes stars. As the core nucleus for cefpodoxime, this molecule acts as a foundation for a range of cephalosporin antibiotics, which doctors use to fend off bacterial infections from bronchitis to urinary tract infections.
Cephalosporins like these rely on 7-AMCA for their backbone. Chemists take this nucleus and tweak its chemical side chains to tailor the drug for different bacteria. By modifying the nucleus, scientists can make a new wave of medicines, each one fighting bugs with slightly different tactics. This flexibility matters because bacteria keep evolving – the battle never truly ends.
Every time I watched a child recover from strep throat on a cephalosporin, or an older patient avoid hospital thanks to an oral prescription, it brought home the real-world difference these molecules make. 7-AMCA might be invisible to most patients, but its role as a starting material shaped the outcome. Solid experience tells me the supply chain for active pharmaceutical ingredients like this one determines whether pharmacies stay stocked or not.
No health system can escape the challenge of antibiotic resistance. Compounds based on 7-AMCA have been tweaked and refined over decades, often taking the front line when older antibiotics stop working. Pharmaceutical manufacturers keep returning to these cephalosporin cores because they give doctors tools that still defeat evolving bacteria. In my experience, rural clinics in particular need reliable drugs like cefpodoxime because backup supplies are slim and infections grow fast.
One of the biggest practical problems now comes from an overuse of these drugs, occasionally without a solid diagnosis. Talking with doctors in community hospitals, I learned the concern is real: if resistance rises, future infections might outrun our best options. Continuous research helps spark new chemical variants of the 7-AMCA nucleus, widening the arsenal. At the same time, building out diagnostics and stewardship programs makes prescriptions more exact, reducing guesswork.
The global pharmaceutical sector faces pressure to shore up high-purity supplies of nuclei like 7-AMCA. Too many recalls and shortages come from lapses in quality control or supply chain bottlenecks in the raw material markets. It’s become clear to me that healthier collaboration between regulators, manufacturers, and independent quality testers helps ensure these critical ingredients reach the factories that need them.
Understanding what’s behind the label matters. The history of 7-AMCA touches the lives of real people and embodies decades of chemical and clinical problem solving. Keeping these core compounds effective and available means doctors will keep winning battles against infections that once turned deadly.
After spending years working around warehouses, pharmacies, and even a family bakery, I picked up a thing or two about storage conditions. The question might sound technical, but it impacts everyone. Whether you’re a supplier, pharmacist, chef, or just someone who wants their groceries to last, how you store things matters more than people often realize. Even the best-made products lose value in the wrong environment.
Let’s talk temperature. Just last summer, I watched a crate of high-end chocolate melt on a loading dock—money down the drain, all because someone ignored the “keep cool” label. Heat messes with food and medicine, causing spoilage and reduced potency. The World Health Organization stresses storage between 15°C and 25°C for most medicines. For food, the FDA suggests a similar range—room temperature for dry goods, cooler ranges for perishables.
Light causes its own problems. Think of vitamins or essential oils stored in clear containers. Exposure to sunlight breaks compounds down, making products less effective or even unsafe. My pharmacist friend says they always reach for brown or opaque bottles because they block UV. Even at home, putting bottles in a cupboard instead of a windowsill extends shelf life noticeably.
Moisture gets less attention but causes plenty of damage. Years ago, I lost a whole season’s worth of flour and sugar to humidity. Mold and clumping sneak in, especially in areas without air conditioning. Food safety authorities recommend keeping these products below 60% relative humidity. Dryness helps preserve everything from grains to medication.
Bags and boxes only do so much. If seals aren’t tight, air and pests get in. I’ve opened more than one storage bin to find tiny bugs ruining everything. I now use airtight containers, especially in warm climates where storage insects thrive. The CDC recommends this approach too—it’s basic, but it works, and it saves money.
Placement inside your home or shop makes a difference. Never store products right on a concrete floor; moisture can creep in. Pallets or racks lift items off the ground, improving air circulation. In the bakery, we kept products away from ovens and fridges to avoid temperature swings, which can be worse than steady heat.
Ignoring storage conditions hurts everyone. Poorly stored medicine loses effectiveness, putting people at risk. Food wasted by bad storage wastes not just money, but water, fuel, and labor built into that product. The CDC estimates that about a third of food in the US gets thrown out, and bad storage plays a role in that.
Labels and advice have meaning. They’re based on real research and experience—such as those from the USDA or FDA. Whether it’s for home or business, I always run through a mental checklist: cool space, out of the sun, dry and sealed tight, clearly marked. Staff training in retail or healthcare should revisit storage basics. For households, a regular pantry cleanout goes further than any fancy technology. Attention to storage keeps people safer, saves money, and cuts waste. That’s something everyone can act on, no warehouse required.
Every pharmacy student remembers the lesson about cefpodoxime proxetil and its unique place in the cephalosporin family. This antibiotic treats a host of bacterial infections, especially for those who cannot tolerate penicillins. Its power sits in its nucleus—a chemical backbone that holds together the features needed for fighting bacteria. The molecular formula for the nucleus of cefpodoxime proxetil is C15H17N5O6S2. This formula represents the cephalosporin “core,” carved out to focus only on the active antimicrobial machinery without all the prodrug side-chains.
The structure of this nucleus starts with a four-membered ß-lactam ring fused to a six-membered dihydrothiazine ring, which is classic for third-generation cephalosporins. A methoxyimino group at the 7-position pushes back against ß-lactamases, those troublesome enzymes that bacteria use to punch holes in most older antibiotics. The nucleus also has an aminothiazole ring at the 3’-position, boosting its shielding power and expanding the range of bugs it can target. This combination of molecular “hardware” has helped extend the drug’s lifetime, supporting doctors facing resistance issues.
For someone caring for patients, understanding this molecular architecture gives clarity about how cefpodoxime fits into therapy. The rings and side chains shape the spectrum—meaning which bacteria fall to the drug. Bacteria evolve, always searching for new ways to punch through antibiotics. Those resistant strains often produce ß-lactamase enzymes, so the methoxyimino group in cefpodoxime’s nucleus helps the drug survive the onslaught. Real-world data from hospitals show that resistant Escherichia coli and Klebsiella pneumoniae infections have challenged doctors for decades. Adding drugs like cefpodoxime has allowed us to stay one step ahead—at least for now.
Every time a cephalosporin is used in clinics, bacteria get one more chance to adapt. Overuse and misuse speed up this process. Resistance can appear even with third-generation drugs. Recent CDC reports show more bacteria producing extended-spectrum ß-lactamases, which even the cleverly-built cefpodoxime nucleus cannot escape. To hold on to these antibiotics, hospitals focus on stewardship—reviewing every prescription and keeping these drugs for when they are truly needed. Patients, in turn, learn that finishing the full course matters, not skipping doses and not stockpiling leftovers.
Chemists keep searching for new ways to strengthen the nucleus of cephalosporins, attaching different groups to boost stability and power. Newer cephalosporins and combinations with ß-lactamase inhibitors promise more answers, but none of these should take away the responsibility we all share—use antibiotics wisely, protect their future use, and keep learning how these molecular blueprints defend lives. Every step in structural innovation stands on careful science, teamwork between doctors and pharmacists, and public awareness about antibiotic resistance. That’s where the battle is fought—one molecule at a time.
Every time a new product or medicine pops up, the spotlight shifts to what goes right, but folks often look past what can go wrong. People want quick results, relief or better health—yet there’s always another side to the coin. Taking the simple step of reading the label and talking with your doctor often gets skipped. People have busy lives. Still, skipping these steps leads to real risks that many only recognize after learning the hard way.
Nearly every pill, cream, or supplement comes with a list of possible responses your body might have. Some cause only a passing headache or mild upset stomach. Others pack a bigger punch—rashes, dizziness, anxiety, or worse. I’ve seen neighbors sidelined by a simple over-the-counter pain reliever, with hives and shortness of breath. These stories don’t make headlines, but they play out in ordinary households all the time.
Doctors keep track for a reason. A report from the U.S. Food and Drug Administration notes that medication reactions send thousands to emergency rooms each year. Ignoring that risk just to save time can set you up for a nasty surprise.
It’s easy to grab something off the drugstore shelf, thinking you know your body well enough. People add supplements and herbal teas to their daily routine, not realizing those harmless-looking items might clash with prescriptions or each other. I remember a relative loading up on cold medicine while already taking blood pressure pills, thinking that if it’s sold over the counter, it can’t hurt. She felt faint and landed at urgent care.
It’s not stubbornness; folks just trust what they know. Bigger warning labels and honest conversations with pharmacists could steer more people away from unwanted side effects. Knowledge beats guesswork every time.
Children, seniors, and pregnant women often react differently to the same dose a healthy adult tolerates. This isn’t about fear—it’s about biology. Kids process things slower, seniors break down drugs in their liver at a crawl, and pregnant women juggle enough changes without extra variables. For these groups, a run-of-the-mill allergy tablet or skin cream can hit much harder. Unclear directions or vague warnings leave people guessing, and the smallest mistake creates big problems.
Clear education changes outcomes. Pharmacists, doctors, and nurses see the effects every day. Spending that extra five minutes to explain what to watch for—nausea, trouble breathing, hives—builds trust and and keeps families out of the hospital. Visual guides and digital apps could nudge people to double-check before swallowing a new pill.
Transparency from manufacturers helps too. Hiding side effects in small print or using technical language cuts out most people and erodes trust. Regulators and healthcare providers should push for larger text, simpler language, and even QR codes that connect to straightforward explanations. Friends and family can play a role by sharing their own stories so others learn what to expect.
No medicine or remedy works the same way for everyone. It makes sense to ask questions, listen, and pay attention to your own body’s warnings. These small actions matter much more than most people realize—sometimes they make all the difference.
Chemical compounds show up in more forms than most would think. Folks from academic labs to food manufacturers ask about purity, but not every product promises the same level. Technical grades pop up for folks who don’t need high specs. Purity sits lower—in the ballpark of 90% to 95%—and trace contaminants aren’t a big concern here. That works well for large-scale industries where the focus is raw performance, not picky analysis.
Step up to reagent-grade and you hit a different crowd. University chemists, QC techs, and small-batch producers pick this grade because the numbers, often above 98%, tell them what’s in the bottle. Analytical work, pharma synthesis, or sensitive assays demand that the side components stay as tiny as possible.
ACS or pharmaceutical grades ask even more. These go through stricter tests. Purities climb beyond 99% with documentation to back every fraction of a percent. If a compound travels into the human body, lands in critical medical tools, or supports advanced research, only these levels get a green light. Stories about recalls and lab errors often trace back to someone grabbing a cheaper grade for a job that called for the best.
Bulk chemicals usually ship in big drums, lined fiber containers, or industrial sacks. For paints, plastics, cleaning agents, most folks aren’t spending on glass or airtight plastics. Cost, weight, and ease of handling win out here. I spent years in a plant where these containers rolled in by the ton and nobody blinked at a dent or a small tear, as long as the product stayed away from moisture and dirt.
Move to high-value or high-risk applications, and the game changes. Flame-sealed glass bottles, aluminum pouches, and inert gas-filled ampoules aren’t just marketing. These shields keep water, air, and stray bits from ruining the product. Analytical labs lose sleep over contamination. Even a grain of dust in a 99.99% sample can mean false data or ruined tests. My graduate group shared horror stories of bad batches that set us back weeks. Tight packaging turned those headaches from regular events into rare exceptions.
Smaller packs matter, too. Not every customer wants 25 kilos. Specialty users—researchers, startups, even hospitals—need 1-gram vials or 100-gram jars. Too large a pack means wasted money or the risk of the material degrading between uses. When suppliers get creative, such as vacuum-sealing micro-packs or portioning out single-use sachets, waste drops and users see better results.
Labels shouldn’t confuse people. A clear grade, batch traceability, and straightforward packaging options tell you whether to trust what’s inside. Product sheets only help if they show actual test data, not just broad claims. More companies have begun offering scan-to-trace codes and QR links to certificates, letting buyers check specifics before they buy or use the material. That’s real peace of mind. If I had that early in my career, I’d have avoided plenty of headaches.
Better yet, suppliers responding to questions or custom needs build long-term trust. A simple packaging option or assurance about purity helps everyone—not just folks in white coats, but any business relying on that compound to do what it’s supposed to do. Confidence in supply chains and materials isn’t a marketing buzzword, it’s what makes science and industry move forward without losing sleep.
| Names | |
| Preferred IUPAC name | (6R,7R)-7-amino-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Other names |
Cefpodoxime Proxetil Nucleus 7-AMCA 7-Amino-3-Methoxymethyl-3-Cephem-4-Carboxylic Acid Proxetil Cefpodoxime Cefpodoximum Proxetilum Cefpodoxime ester |
| Pronunciation | /ˌsɛf.poʊˈdɒk.sɪm proʊkˈsɛtɪl ˈnjuː.kli.əs ˈsɛv.ən ˈæm.kə ˈsɛv.ən əˈmiː.noʊ θri mɪˈθɒk.siˌmɛθ.əl θri ˈsɛf.əm fɔr kɑːrˈbɒk.sɪl.ɪk ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | ["957-68-6"] |
| 3D model (JSmol) | `3Dmol.js|7-AMCA|CC1C2C(=O)N(C(=O)CS2(=C(S1)N)C)C(=O)O` |
| Beilstein Reference | 1755191 |
| ChEBI | CHEBI:131729 |
| ChEMBL | CHEMBL19214 |
| ChemSpider | 127912 |
| DrugBank | DB01416 |
| ECHA InfoCard | 03e8ae3e-7131-4743-9363-6f3ce8a8e4be |
| EC Number | 87197-70-2 |
| Gmelin Reference | 89859 |
| KEGG | C01343 |
| MeSH | D000831 |
| PubChem CID | 656738 |
| RTECS number | SW2480000 |
| UNII | EM8M5UV72T |
| UN number | UN number not assigned |
| CompTox Dashboard (EPA) | DTXSID9020823 |
| Properties | |
| Chemical formula | C10H11N3O4S |
| Molar mass | 327.35 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.82 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -1.05 |
| Vapor pressure | 0.0 mmHg at 25°C |
| Acidity (pKa) | 2.5 |
| Basicity (pKb) | 7.2 |
| Refractive index (nD) | 1.65 |
| Dipole moment | 3.1762 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 385.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -1074 kJ/mol |
| Pharmacology | |
| ATC code | J01DD13 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07, GHS08 |
| Pictograms | 🧪💊🔬 |
| Signal word | Warning |
| Hazard statements | H317: May cause an allergic skin reaction. H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| Precautionary statements | Do not breathe dust. Avoid contact with skin and eyes. Wear suitable protective clothing, gloves, and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| Flash point | > 230.2 °C |
| Autoignition temperature | > 340°C |
| LD50 (median dose) | LD50 (median dose): Mouse oral LD50 = 5 g/kg |
| NIOSH | Not listed |
| PEL (Permissible) | 10 µg/m³ |
| REL (Recommended) | 2-8°C |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Cefpodoxime Cefpodoxime Proxetil 7-ACA (7-Aminocephalosporanic acid) Cefixime Nucleus (7-ATCA) Ceftibuten Nucleus Cefdinir Nucleus Cefuroxime Nucleus 7-ADCA (7-Aminodeacetoxycephalosporanic acid) |
